Dermira Prices $130.0 Million Public Offering of Common Stock
20 March 2019 - 10:36AM
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions, today announced the pricing of its
underwritten public offering of 9,811,321 shares of its common
stock at a price to the public of $13.25 per share. The gross
proceeds to Dermira from the offering, before deducting the
underwriting discounts and commissions and estimated offering
expenses, are expected to be approximately $130.0 million. In
addition, Dermira has granted the underwriters a 30-day option to
purchase up to an additional 1,471,698 shares of its common stock,
on the same terms and conditions. All of the shares will be offered
and sold by Dermira.
Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim
Securities are acting as book-runners for the offering. Needham
& Company and H.C. Wainwright & Co. are acting as
co-managers.
The public offering is being made pursuant to a shelf
registration statement on Form S-3 that was filed by Dermira with
the Securities and Exchange Commission (“SEC”) on November 7, 2018
and was declared effective on November 21, 2018. A final
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering will be filed with
the SEC and will be available on the SEC's website
at www.sec.gov. When available, copies of the final prospectus
supplement and accompanying prospectus may be obtained from
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
Attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at 800-831-9146; Cowen and
Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at 631-274-2806; Cantor
Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor, New York, NY 10022, or by email at
prospectus@cantor.com; and Guggenheim Securities, LLC, Attention:
Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New
York, NY 10017, by telephone at 212-518-9658, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy Dermira’s common stock, nor shall
there be any sale of Dermira’s common stock in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Contacts:
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Investors:Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024